|
|
| Line 3: |
Line 3: |
| | <StructureSection load='6sal' size='340' side='right'caption='[[6sal]], [[Resolution|resolution]] 1.61Å' scene=''> | | <StructureSection load='6sal' size='340' side='right'caption='[[6sal]], [[Resolution|resolution]] 1.61Å' scene=''> |
| | == Structural highlights == | | == Structural highlights == |
| - | <table><tr><td colspan='2'>[[6sal]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6SAL OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6SAL FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[6sal]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6SAL OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6SAL FirstGlance]. <br> |
| - | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=L3E:4-[(~{E})-[3-[2-chloranyl-6-(trifluoromethyl)phenyl]-5-(1~{H}-pyrrol-3-yl)-1,2-oxazol-4-yl]methylideneamino]benzoic+acid'>L3E</scene></td></tr> | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.61Å</td></tr> |
| - | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">RORC, NR1F3, RORG, RZRG ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
| + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=L3E:4-[(~{E})-[3-[2-chloranyl-6-(trifluoromethyl)phenyl]-5-(1~{H}-pyrrol-3-yl)-1,2-oxazol-4-yl]methylideneamino]benzoic+acid'>L3E</scene></td></tr> |
| - | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6sal FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6sal OCA], [http://pdbe.org/6sal PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6sal RCSB], [http://www.ebi.ac.uk/pdbsum/6sal PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6sal ProSAT]</span></td></tr> | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6sal FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6sal OCA], [https://pdbe.org/6sal PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6sal RCSB], [https://www.ebi.ac.uk/pdbsum/6sal PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6sal ProSAT]</span></td></tr> |
| | </table> | | </table> |
| | == Function == | | == Function == |
| - | [[http://www.uniprot.org/uniprot/RORG_HUMAN RORG_HUMAN]] Possible nuclear receptor for hydroxycholesterols, the binding of which strongly promotes coactivators recruitment. Essential for thymopoiesis and the development of several secondary lymphoid tissues, including lymph nodes. Involved in lineage specification of uncommitted CD4(+) T-helper cells into Th17 cells. Regulate the expression of several components of the circadian clock. | + | [https://www.uniprot.org/uniprot/RORG_HUMAN RORG_HUMAN] Possible nuclear receptor for hydroxycholesterols, the binding of which strongly promotes coactivators recruitment. Essential for thymopoiesis and the development of several secondary lymphoid tissues, including lymph nodes. Involved in lineage specification of uncommitted CD4(+) T-helper cells into Th17 cells. Regulate the expression of several components of the circadian clock. |
| | <div style="background-color:#fffaf0;"> | | <div style="background-color:#fffaf0;"> |
| | == Publication Abstract from PubMed == | | == Publication Abstract from PubMed == |
| Line 23: |
Line 23: |
| | __TOC__ | | __TOC__ |
| | </StructureSection> | | </StructureSection> |
| - | [[Category: Human]] | + | [[Category: Homo sapiens]] |
| | [[Category: Large Structures]] | | [[Category: Large Structures]] |
| - | [[Category: Brunsveld, L]] | + | [[Category: Brunsveld L]] |
| - | [[Category: Doveston, R G]] | + | [[Category: Doveston RG]] |
| - | [[Category: Meijer, F A]] | + | [[Category: Meijer FA]] |
| - | [[Category: Vries, R M.J M.de]] | + | [[Category: De Vries RMJM]] |
| - | [[Category: Allosteric]]
| + | |
| - | [[Category: Gene regulation]]
| + | |
| - | [[Category: Inhibitor]]
| + | |
| - | [[Category: Inverse agonist]]
| + | |
| - | [[Category: Nuclear receptor]]
| + | |
| Structural highlights
Function
RORG_HUMAN Possible nuclear receptor for hydroxycholesterols, the binding of which strongly promotes coactivators recruitment. Essential for thymopoiesis and the development of several secondary lymphoid tissues, including lymph nodes. Involved in lineage specification of uncommitted CD4(+) T-helper cells into Th17 cells. Regulate the expression of several components of the circadian clock.
Publication Abstract from PubMed
Retinoic acid receptor-related orphan receptor gammat (RORgammat) is a nuclear receptor associated with the pathogenesis of autoimmune diseases. Allosteric inhibition of RORgammat is conceptually new, unique for this specific nuclear receptor, and offers advantages over traditional orthosteric inhibition. Here, we report a highly efficient in silico-guided approach that led to the discovery of novel allosteric RORgammat inverse agonists with a distinct isoxazole chemotype. The the most potent compound, 25 (FM26), displayed submicromolar inhibition in a coactivator recruitment assay and effectively reduced IL-17a mRNA production in EL4 cells, a marker of RORgammat activity. The projected allosteric mode of action of 25 was confirmed by biochemical experiments and cocrystallization with the RORgammat ligand binding domain. The isoxazole compounds have promising pharmacokinetic properties comparable to other allosteric ligands but with a more diverse chemotype. The efficient ligand-based design approach adopted demonstrates its versatility in generating chemical diversity for allosteric targeting of RORgammat.
Ligand-Based Design of Allosteric Retinoic Acid Receptor-Related Orphan Receptor gammat (RORgammat) Inverse Agonists.,Meijer FA, Doveston RG, de Vries RMJM, Vos GM, Vos AAA, Leysen S, Scheepstra M, Ottmann C, Milroy LG, Brunsveld L J Med Chem. 2019 Dec 24. doi: 10.1021/acs.jmedchem.9b01372. PMID:31821760[1]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
References
- ↑ Meijer FA, Doveston RG, de Vries RMJM, Vos GM, Vos AAA, Leysen S, Scheepstra M, Ottmann C, Milroy LG, Brunsveld L. Ligand-Based Design of Allosteric Retinoic Acid Receptor-Related Orphan Receptor gammat (RORgammat) Inverse Agonists. J Med Chem. 2019 Dec 24. doi: 10.1021/acs.jmedchem.9b01372. PMID:31821760 doi:http://dx.doi.org/10.1021/acs.jmedchem.9b01372
|
